January 12, 2018 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Basel, 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS) An important new treatment option for people with active relapsing forms of... Read more

January 8, 2018 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

January 8, 2018 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

Chicago, USA Jan 8, 2018 – GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients. The two companies... Read more

January 8, 2018 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

December 22, 2017 Licensing, IP, and Legal

Cellular Dynamics International Sends Human iPSC-Derived Cardiomyocytes To International Space Station On NASA Resupply Mission

Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Astrocytes iCell Cardiac Progenitor Cells iCell Cardiomyocytes iCell Cardiomyocytes2 iCell DopaNeurons iCell Endothelial Cells iCell GABANeurons iCell GlutaNeurons iCell Hematopoietic Progenitor Cells iCell Hepatoblasts iCell Hepatocytes... Read more

December 20, 2017 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership

Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership WALTHAM, Mass., Dec. 20, 2017 /PRNewswire/ — Juno Therapeutics (NASDAQ: JUNO) and Thermo Fisher Scientific have entered into a partnership for Juno to use Thermo Fisher’s Cell Therapy Systems (CTS) activation reagents in the manufacturing of its chimeric antigen receptor T cell (CAR T)... Read more

December 15, 2017 Licensing, IP, and Legal

QIAGEN and Oxford Immunotec settle patent infringement lawsuit

Germantown, Maryland, and Hilden, Germany, December 15, 2017 – QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN’s QuantiFERON®-TB... Read more

December 15, 2017 Licensing, IP, and Legal

QIAGEN and Oxford Immunotec settle patent infringement lawsuit

Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation Germantown, Maryland, and Hilden, Germany, December 15, 2017 – QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District... Read more

December 13, 2017 Licensing, IP, and Legal M&A, Partnerships

Bruker and The Metropolitan Museum of Art Announce Partnership in the Field of Cultural Heritage Science

NEW YORK and BILLERICA, Mass., Dec. 13, 2017 /PRNewswire/ — The Metropolitan Museum of Art (The Met) and Bruker Corporation are pleased to announce a 10-year partnership to advance novel analytical technologies and methods in the field of cultural heritage science even further.  This partnership builds upon and expands a long history of collaboration that has... Read more